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ABSTRACT
We In a cross-sectional study, the basal and interferon-p (IFN-P) stimulated (1000 IU/ml) NK cell activity of 15 hGHdeficient patients and 15 age-and sex-matched controls was measured.
The percentages and absolute numbers of CD3./16+ NK-cells were not significantly different in the patient vs. control group. The basal and IFN-P stimulated NK cell activity however was significantly decreased in the patient vs. control group at all effecter/target (E/T) cell ratios from 12.5-100 (e.g. 17 ? 3 vs. 28 ? 3% lysis without IFN-P, P < 0.05, and 42 t 4 vs. 57 2 4% lysis with IFN-0, P < 0.05; both at E/T 50). IGF-I levels of patients and controls showed a significant positive correlation with NK cell activity (r = 0.37; P < 0.05).
In an IGF-I in vitro study (IGF-I in vitro 250-1250 kg/L), the basal and IFN-P stimulated NK cell activity of 13 hGH-deficient patients and of 18 normal subjects was significantly enhanced by IGF-I in vitro (e.g.
GH-deficient patients: 9 ? 2 us. 10 2 2% lysis without IFN-P, P < 0.05 and 25 + 4 vs. 30 + 4% lysis with IFN-/3, P < 0.005; and normal subjects:
15 + 3 vs. 23 ? 3% lysis without IFN-/3, P < 0.001 and 35 2 4 us. 44 + 5% lysis with IFN-P, P < 0.001; both at IGF-I 500 pg/L). In summary, in our cross-sectional study, adult GH-deficient patients showed a significantly lower basal and IFN-P stimulated NK cell activity than matched controls, despite equal NK cell numbers. IGF-I levels of patients and controls showed a weak positive correlation with NK cell activity.
In an in vitro study, IGF-I significantly enhanced basal and IFN-P stimulated NK cell activity of hGH-deficient patients and also of normal subjects. NK cells (9 t 2 ~1s. 11 + 2% and 0.195 + 0.032 us. 0.222 k 0.051 G/L) did not differ significantly between the hGH-deficient patients and controls. The basal as well as the IFN-/3 stimulated NK cell activity were significantly lower in hGH-deficient patients than in age-and sex-matched controls at all tested effector-target cell ratios from 12.5-100 (Fig. 1) . However, stimulation with IFN-/3 caused an increase of NK cell activity in both groups, and the absolute increase from basal to IFN-P stimulated NK cell activity was not signficantly different in the hGH-deficient patients 11s. the age-and sex-matched controls. In the combined analysis of adult hGH-deficient patients and age-and sex-matched controls, Pearsson's correlation performed after assuring normal distribution of data (Kolmogorov-Smirnov test P > 0.10) revealed a positive association of IGF-I levels with summarized basal and IFN-/3 stimulated NK cell activity, which was significant (R = 0.37; P < 0.05; Fig. 2 ).
IGF-I in vitro study
In 18 normal subjects IGF-I in z~jtro at final concentrations of 250,500, and 1250 pg/liter caused a significant increase of basal NK cell activity (14 k 3% without IGF-I us. 20 '-3,23 -t 3, and 22 + 3% lysis, P < 0.01). IFN-P stimulated NK cell activity was also significantly increased by IGF-I in vitro (35 2 4% without IGF-I us. 43 k 4, 44 k 5, and 45 + 5% lysis, P < 0.001) (Fig. 3) .
In 13 hGH-deficient adult patients, IGF-I in vitro at final concentrations of 250, 500, and 1250 pg/liter also caused a small but significant increase of basal NK cell activity (9 2 2% without IGF-I vs. 10 2 2, ns., 10 2 2, and 11 2 2% lysis, P < 0.05). IFN-0 stimulated NK cell activity was also significantly increased by IGF-I in vitro (25 2 4% without IGF-I vs. 30 + 4, 30 2 4, and 30 C 4% lysis, P < 0.01) (Fig. 4) . 
Discussion
We have shown that the NK cell activity is significantly decreased in hGH-deficient adult patients in comparison with age-and sex-matched controls despite comparable and normal NK cell numbers. These results are in agreement with several studies on hGH-deficient children describing a decreased NK cell activity despite normal NK cell numbers (11-13). In hGH-deficient children, NK cell activity has been shown to increase during hGH replacement therapy (13). We have also shown that in a combined analysis of hGH-deficient adult patients and age-and sex-matched controls together, the serum IGF-I level correlates significantly with NK cell activity. This analysis was performed after assuring normal distribution of data in both datasets by KolmogorovSmirnov test. This finding is in agreement with a study from Crist et nl. (14), who reported a similar correlation between serum IGF-I levels and NK cell activity in women with impaired endogenous GH secretion. We observed no significant correlation between IGFBP-3 serum levels and NK cell activity (data not shown).
However, in adults IGFBP-3 in comparison to IGF-I has been reported to be a rather weak parameter for the assessment of the GH secretory status (22, 23). Therefore, we believe that finding no association between IGFBP-3 and NK cell activity is caused by the poor reflection of the GH-secretory-status by IGFBP-3. To the best of our knowledge there do not exist any data on the in vitro effects of GH on NK cell activity or NK number. As IGF-I and GH-receptors have both been demonstrated to exist on NK cells (5-7), in addition to the described effects of IGF-I on NK cell activity, GH may directly play a role in modulating NK cell activity.
In our cross-sectional study of hGH-deficient adult patients the NK cell activity was found to be increased by stimulation with 1000 III/ml IFN-/3 in vitro to the same extent as in age-and sex-matched controls. These results are in contrast to the findings Further studies therefore should use lower, more physiological concentrations of "free" IGF-I. IFN-/3 and IGF-I in vitro appear to have an independent, additive effect on NK cell activity. IFN-P in vitro has been reported not to affect the levels of GH mRNA in NK cells, and GH has been found not to induce IFN production (25). To the best of our knowledge, similar data on possible interactions of IGF-I and IFN do not exist.
Furthermore, we were able to demonstrate, that IGF-I in vitro can increase the basal and IFN-/3 stimulated NK cell activity of hGH-deficient adult patients. The increase of basal NK cell activity in hGH-deficient adult patients by IGF-I in vitro, although statistically significant, was very small. This may be caused by the low basal NK cell activity of hGHdeficient adult patients being close to the lower detection limit of the NK assay system. At the higher IFN-/3 stimulated NK cell activities in hGH-deficient patients, however, we could demonstrate a profound increase of NK cell activity by IGF-I in vitro. These in vifro data and the data on the positive association between serum IGF-I levels and NK cell activity indicate that NK cell activity in hGH-deficient patients might be decreased because of lower serum levels of IGF-I, and NK cell activity can be increased by elevating the IGF-I serum levels. However, an additional direct effect of GH on NK cell activity, teleologically hypothesized because of GH receptor expression on NK cells, still remains to be demonstrated. In summary, basal and IFN-/3 stimulated NK cell activity was found to be decreased in hGH-deficient adult patients in comparison to age-and sex-matched controls, despite equal NK cell numbers. NK cell activity was stimulated by IFN-P in hGHdeficient adult patients and in age-and sex-matched controls, indicating that there does not exist a functional defect of the NK cells in hGH-deficient adult patients. Serum IGF-I levels and NK cell activity showed a positive correlation.
IGF-I in vitro increased basal and IFN-/3 stimulated NK cell activity in normal subjects and in hGH-deficient adult patients. NK cell activity in GH deficiency might be decreased indirectly, because of lower serum levels of IGF-I. Recently, Watanabe et al. (15) suggested GH deficiency to be a risk factor for leukemia and hypothesized low NK cell activity to be a possible explanation for GH deficiency being related to the risk of leukemia. The role of NK cell activity in leukemia is not completely understood (26). In an attempt to elucidate a clinically important aspect of GH deficiency syndrome, further studies should focus on the relationship of GH deficiency, decreased NK cell activity, and the incidence of leukemia.
